NCT02211755View on ClinicalTrials.gov

Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 6, 2014

Primary Completion Date

August 14, 2025

Study Completion Date

August 15, 2025

Conditions
NeoplasmsMyelodysplastic SyndromesLymphomas
Interventions
DRUG

Bortezomib plus Clofarabine

The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02211755 - Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors | Biotech Hunter | Biotech Hunter